Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Watanabe, T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Watanabe, T
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology Pages 77-80

Phase III Randomized Comparison of Postoperative Adjuvant Chemotherapy with 2-Year Oral UFT (Uracil/Tegafur) versus Six-cycle CMF (Cyclophosphamide/Methotrexate/5-Fluorouracil) in High-risk Node-Negative Breast Cancer Patients
   Identification Number
   Chief Investigator
   Date Activated
   Therapy Modality
Background
Objectives
Protocol Entry Criteria
   Disease Characteristics
   Patient Characteristics
   Other criteria
   Randomization
   Treatment Regimens
   Projected Accrual
   Projected Accrual Duration
   Projected Follow-Up Duration
   Sponsor Of The Study
   Data Management
   Chief Statistitian
   Participating Organizations
References

Phase III Randomized Comparison of Postoperative Adjuvant Chemotherapy with 2-Year Oral UFT (Uracil/Tegafur) versus Six-cycle CMF (Cyclophosphamide/Methotrexate/5-Fluorouracil) in High-risk Node-Negative Breast Cancer Patients

Phase III Randomized Comparison of Postoperative Adjuvant Chemotherapy with 2-Year Oral UFT (Uracil/Tegafur) versus Six-cycle CMF (Cyclophosphamide/Methotrexate/5-Fluorouracil) in High-risk Node-Negative Breast Cancer Patients

IDENTIFICATION NUMBER

N·SASBC-01 (National Surgical Adjuvant Study of Breast Cancer Protocol 01)

CHIEF INVESTIGATOR

Toru Watanabe, MD, PhD
Department of Medical Oncology,
National Cancer Center Hospital,
Tokyo, Japan

DATE ACTIVATED

October 14, 1996

THERAPY MODALITY

Chemotherapy, postoperative adjuvant therapy, post-marketing clinical trial

BACKGROUND

Use of surgical adjuvant chemotherapy employing a combination of cytotoxic drugs, e.g. CMF . . . [Full Text of this Article]

OBJECTIVES

PROTOCOL ENTRY CRITERIA

Disease Characteristics

Patient Characteristics

Other criteria

Randomization

TREATMENT REGIMENS

PROJECTED ACCRUAL

PROJECTED ACCRUAL DURATION

PROJECTED FOLLOW-UP DURATION

SPONSOR OF THE STUDY

DATA MANAGEMENT

CHIEF STATISTITIAN

PARTICIPATING ORGANIZATIONS

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?